Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck

被引:18
作者
Planting, AST
deMulder, PHM
deGraeff, A
Verweij, J
机构
[1] UNIV NIJMEGEN HOSP,DEPT MED ONCOL,NL-6500 HB NIJMEGEN,NETHERLANDS
[2] UNIV UTRECHT HOSP,DEPT INTERNAL MED,UTRECHT,NETHERLANDS
关键词
head and neck cancer; cisplatin; phase II study; dose intensity;
D O I
10.1016/S0959-8049(96)00311-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In a phase I study of weekly administered cisplatin, we observed a major response in 8 of 9 patients with locally far advanced head and neck cancer. Therefore, a phase II study was initiated to explore the activity and tolerance of this weekly cisplatin regimen. 59 patients with locally advanced head and neck cancer were entered into this phase II study. Cisplatin was administered at a dose of 80 mg/m(2) weekly for 6 cycles. Cisplatin was administered in hypertonic saline (3% NaCl) as a 3-h infusion with standard pre- and posthydration. 51 patients were evaluable for response and 55 for toxicity. Only 9 patients were able to complete the treatment with the planned dose intensity of 80 mg/m(2)/week. Complete disappearance of the tumour was observed in 8 patients and a partial response in 22 (response rate 59%; 51% of all eligible patients 95% CI limits 37-63%). Stable disease was observed in 12 patients, and the tumour progressed in 9 patients. 47 patients subsequently received high-dose radiotherapy, 1 radiotherapy and surgery and 4 patients second-line chemotherapy. The median progression-free survival and median overall survival for all patients were 32 weeks and 56 weeks, respectively. Haematological toxicity consisted of anaemia, leucocytopenia (grade 3 + 4 in 17 patients) and thrombocytopenia (grade 3 + 4 in 17 patients). Because of leuco- and/or thrombocytopenia, treatment was delayed in 30 patients while 13 were taken off the study because of delayed bone marrow recovery. Non-haematological toxicities were: ototoxicity grade 1 in 3 patients, grade 2 in 7 and grade 3 in 3 patients; nephrotoxicity grade I in 13 patients, grade 2 in 2 and grade 3 in I patient. Neurotoxicity grade I was observed in only 8 patients. Cisplatin, as a single agent, administered at high-dose intensity, has an antitumour activity comparable with that of combination regimens in locally advanced head and neck cancer. The pattern of toxicity is different: leuco- and thrombocytopenia jeopardise the dose intensity concept; for patients ototoxicity is the more relevant toxicity. Further studies with weekly cisplatin are of interest particularly with newer measures to reduce toxicity. (C) 1997 Elsevier Science Ltd.
引用
收藏
页码:61 / 65
页数:5
相关论文
共 50 条
[41]   Phase I Study of C-TPF in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck [J].
Haddad, Robert I. ;
Tishler, Roy B. ;
Norris, Charles ;
Goguen, Laura ;
Balboni, Tracy A. ;
Costello, Rosemary ;
Wirth, Lori ;
Lorch, Jochen ;
Andreozzi, Britta ;
Annino, Donald ;
Posner, Marshall R. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) :4448-4453
[42]   A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck [J].
Caponigro, Francesco ;
Romano, Carmen ;
Milano, Amalia ;
Solla, Raffaele ;
Franchin, Giovanni ;
Adamo, Vincenzo ;
Mari, Ettore ;
Morrica, Brunello ;
Pepe, Stefano .
ANTI-CANCER DRUGS, 2008, 19 (07) :739-744
[43]   Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck [J].
Aguilar-Ponce, JL ;
Granados-García, M ;
Villavicencio, V ;
Poitevin-Chacón, A ;
Green, D ;
Dueñas-González, A ;
Herrera-Gómez, A ;
Luna-Ortiz, K ;
Alvarado, A ;
Martínez-Said, H ;
Castillo-Henkel, C ;
Segura-Pacheco, B ;
De la Garza, J .
ANNALS OF ONCOLOGY, 2004, 15 (02) :301-306
[44]   Phase I Study of Nedaplatin Prior to S-1 in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma [J].
Sato, Dai ;
Kogashiwa, Yasunao ;
Tsukahara, Kiyoaki ;
Yamauchi, Koichi ;
Kohno, Naoyuki .
CHEMOTHERAPY, 2013, 59 (04) :314-318
[45]   Phase II Study of Cetuximab Plus Concomitant Boost Radiotherapy in Japanese Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck [J].
Okano, Susumu ;
Yoshino, Takayuki ;
Fujii, Masato ;
Onozawa, Yusuke ;
Kodaira, Takeshi ;
Fujii, Hirofumi ;
Akimoto, Tetsuo ;
Ishikura, Satoshi ;
Oguchi, Masahiko ;
Zenda, Sadamoto ;
de Blas, Barbara ;
Tahara, Makoto .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (05) :476-482
[46]   Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer [J].
Guntinas-Lichius, O ;
Appenrodt, S ;
Veelken, F ;
Krug, B .
LARYNGOSCOPE, 2006, 116 (04) :613-618
[47]   Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma [J].
Yao, Min ;
Woods, Charles ;
Lavertu, Pierre ;
Fu, Pingfu ;
Gibson, Michael ;
Rezaee, Rod ;
Zender, Chad ;
Wasman, Jay ;
Sharma, Neelesh ;
Machtay, Mitchell ;
Savvides, Panayiotis .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016, 38 :E1770-E1776
[48]   A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer [J].
André Planting ;
Siang Kho ;
Maria van der Burg ;
H. Goey ;
J. Schellens ;
Martin van den Bent ;
A. van der Gaast ;
Maureen de Boer-Dennert ;
Gerrit Stoter ;
Jaap Verweij .
Cancer Chemotherapy and Pharmacology, 1997, 40 :347-352
[49]   Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer [J].
Gulati, Shuchi ;
Desai, Janki ;
Palackdharry, Sarah M. ;
Morris, John C. ;
Zhu, Zheng ;
Jandarov, Roman ;
Riaz, Muhammad K. ;
Takiar, Vinita ;
Mierzwa, Michelle ;
Gutkind, J. Silvio ;
Molinolo, Alfredo ;
Desai, Pankaj B. ;
Sadraei, Nooshin Hashemi ;
Wise-Draper, Trisha M. .
CANCER, 2020, 126 (02) :354-362
[50]   Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma - A phase II trial [J].
Licitra, L ;
Capri, G ;
Fulfaro, F ;
Grandi, C ;
Tarenzi, E ;
Cavina, R ;
Gianni, L .
ANNALS OF ONCOLOGY, 1997, 8 (11) :1157-1158